Shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) saw unusually-high trading volume on Friday . Approximately 864,086 shares were traded during trading, an increase of 353% from the previous session’s volume of 190,625 shares.The stock last traded at $1.38 and had previously closed at $1.27.
CTXR has been the subject of several recent analyst reports. Zacks Investment Research downgraded Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 18th. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Citius Pharmaceuticals in a research note on Thursday, February 7th.
In related news, insider Myron Z. Holubiak purchased 129,450 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was bought at an average price of $1.55 per share, for a total transaction of $200,647.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 58.52% of the company’s stock.
Citius Pharmaceuticals Company Profile (NASDAQ:CTXR)
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
Featured Story: Trading Ex-Dividend
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.